OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease
-
Published:2003-09
Issue:14
Volume:39
Page:1976-1977
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Demetri George D.
Subject
Cancer Research,Oncology
Reference12 articles.
1. Verweij J, van Oosterom A, Blay J-Y, et al. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39, 2006–2011
2. Stroobants S, Goeminne J, Seegerts M, et al. 18FDG-Positron emission tomography for the early production of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). Eur J Cancer 2003, 39, 2012–2020.
3. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998
4. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor;Heinrich;Blood,2000
5. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein;Tuveson;Oncogene,2001
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献